Altered sarcoplasmic reticulum calcium cycling - Targets for heart failure therapy

Nature Reviews Cardiology

Volumn 9, Issue 12, 2012, Pages 717-733

  Kho, Changwon ^a   Lee, Ahyoung ^a   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; CALSEQUESTRIN; INTRACELLULAR CALCIUM SENSING PROTEIN; PHOSPHOLAMBAN; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SODIUM CALCIUM EXCHANGE PROTEIN; STROMAL INTERACTION MOLECULE 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL; VOLTAGE GATED CALCIUM CHANNEL;

CALCIUM TRANSPORT; CYTOSOL; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HEART MUSCLE CELL; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SARCOLEMMA; SARCOPLASMIC RETICULUM;

ANIMALS; CALCIUM; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC; SARCOPLASMIC RETICULUM;

EID: 84870241098     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.145     Document Type: Review

References (263)

1. de Giuli, F. et al. Incidence and outcome of persons with a clinical diagnosis of heart failure in a general practice population of 696,884 in the United Kingdom. Eur. J. Heart Fail. 7, 295-302 (2005).
2. Sliwa, K., Damasceno, A. & Mayosi, B. M. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 112, 3577-3583 (2005).
3. Jiang, H. & Ge, J. Epidemiology and clinical management of cardiomyopathies and heart failure in China. Heart 95, 1727-1731 (2009).
4. Clapham, D. E. Calcium signaling. Cell 80, 259-268 (1995).
5. Berridge, M. J., Lipp, P. & Bootman, M. D. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 1, 11-21 (2000).
6. Rockman, H. A., Koch, W. J. & Lefkowitz, R. J. Seven transmembrane-spanning receptors and heart function. Nature 415, 206-212 (2002).
7. Antos, C. L. et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ. Res. 89, 997-1004 (2001).
8. Feldman, R. D. & Gros, R. New insights into the regulation of cAMP synthesis beyond GPCR/G protein activation: implications in cardiovascular regulation. Life Sci. 81, 267-271 (2007).
9. Wittkopper, K., Dobrev, D., Eschenhagen, T. & El-Armouche, A. Phosphatase-1 inhibitor-1 in physiological and pathological β-adrenoceptor signalling. Cardiovasc. Res. 91, 392-401 (2011).
10. Reinkober, J. et al. Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade. Gene Ther. 19, 686-693 (2012).
11. Sculptoreanu, A., Rotman, E., Takahashi, M., Scheuer, T. & Catterall, W. A. Voltage-dependent potentiation of the activity of cardiac L-type calcium channel α1 subunits due to phosphorylation by cAMP-dependent protein kinase. Proc. Natl Acad. Sci. USA 90, 10135-10139 (1993).
12. Kamp, T. J. & Hell, J. W. Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ. Res. 87, 1095-1102 (2000).
13. Colyer, J. & Wang, J. H. Dependence of cardiac sarcoplasmic reticulum calcium pump activity on the phosphorylation status of phospholamban. J. Biol. Chem. 266, 17486-17493 (1991).
14. Haghighi, K., Gregory, K. N. & Kranias, E. G. Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 322, 1214-1222 (2004).
15. Chen, Z., Akin, B. L. & Jones, L. R. Mechanism of reversal of phospholamban inhibition of the cardiac Ca2+-ATPase by protein kinase A and by anti-phospholamban monoclonal antibody 2D12. J. Biol. Chem. 282, 20968-20976 (2007).
16. Li, L., Desantiago, J., Chu, G., Kranias, E. G. & Bers, D. M. Phosphorylation of phospholamban and troponin I in β-adrenergic-induced acceleration of cardiac relaxation. Am. J. Physiol. Heart Circ. Physiol. 278, H769-H779 (2000).
17. Kentish, J. C. et al. Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ. Res. 88, 1059-1065 (2001).
18. Pena, J. R. & Wolska, B. M. Troponin I phosphorylation plays an important role in the relaxant effect of β-adrenergic stimulation in mouse hearts. Cardiovasc. Res. 61, 756-763 (2004).
19. Lohse, M. J., Engelhardt, S. & Eschenhagen, T. What is the role of β-adrenergic signaling in heart failure? Circ. Res. 93, 896-906 (2003).
20. Lyon, A. R. et al. Plasticity of surface structures and β2-adrenergic receptor localization in failing ventricular cardiomyocytes during recovery from heart failure. Circ. Heart Fail. 5, 357-365 (2012).
21. Tilley, D. G. & Rockman, H. A. Role of β-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Rev. Cardiovasc. Ther. 4, 417-432 (2006).
22. Ho, D., Yan, L., Iwatsubo, K., Vatner, D. E. & Vatner, S. F. Modulation of β-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5. Heart Fail. Rev. 15, 495-512 (2010).
23. Perreault, C. L., Bing, O. H., Brooks, W. W., Ransil, B. J. & Morgan, J. P. Differential effects of cardiac hypertrophy and failure on right versus left ventricular calcium activation. Circ. Res. 67, 707-712 (1990).
24. Ungerer, M., Bohm, M., Elce, J. S., Erdmann, E. & Lohse, M. J. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation 87, 454-463 (1993).
25. Kiuchi, K. et al. Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure. J. Clin. Invest. 91, 907-914 (1993).
26. Choi, D. J., Koch, W. J., Hunter, J. J. & Rockman, H. A. Mechanism of β-adrenergic receptor desensitization in cardiac hypertrophy is increased β-adrenergic receptor kinase. J. Biol. Chem. 272, 17223-17229 (1997).
27. Woo, A. Y. & Xiao, R. P. β-adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol. Sin. 33, 335-341 (2012).
28. Grimm, M. & Brown, J. H. β-adrenergic receptor signaling in the heart: role of CaMKII. J. Mol. Cell Cardiol. 48, 322-330 (2009).
29. Wilkins, B. J. et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94, 110-118 (2004).
30. Zhang, C. L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479-488 (2002).
31. Voelkers, M. et al. Orai1 and Stim1 regulate normal and hypertrophic growth in cardiomyocytes. J. Mol. Cell Cardiol. 48, 1329-1334 (2010).
32. Hulot, J. S. et al. Critical role for stromal interaction molecule 1 in cardiac hypertrophy. Circulation 124, 796-805 (2011).
33. Buraei, Z. & Yang, J. The β subunit of voltage-gated Ca2+ channels. Physiol. Rev. 90, 1461-1506 (2010).
34. Andrade, A. et al. The α2δ subunit augments functional expression and modifies the pharmacology of CaV1.3 L-type channels. Cell Calcium 46, 282-292 (2009).
35. Benitah, J. P., Alvarez, J. L. & Gomez, A. M. L-type Ca2+ current in ventricular cardiomyocytes. J. Mol. Cell Cardiol. 48, 26-36 (2010).
36. Seisenberger, C. et al. Functional embryonic cardiomyocytes after disruption of the L-type α1C (Cav1.2) calcium channel gene in the mouse. J. Biol. Chem. 275, 39193-39199 (2000).
37. Weissgerber, P. et al. Reduced cardiac L-type Ca2+ current in CaVβ2-/- embryos impairs cardiac development and contraction with secondary defects in vascular maturation. Circ. Res. 99, 749-757 (2006).
38. Semsarian, C. et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J. Clin. Invest. 109, 1013-1020 (2002).
39. Liao, Y. et al. Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice. Cardiovasc. Res. 65, 879-888 (2005).
40. Mukherjee, R. & Spinale, F. G. L-type calcium channel abundance and function with cardiac hypertrophy and failure: a review. J. Mol. Cell Cardiol. 30, 1899-1916 (1998).
41. Goonasekera, S. A. et al. Decreased cardiac L-type Ca2+ channel activity induces hypertrophy and heart failure in mice. J. Clin. Invest. 122, 280-290 (2012).
42. Schroder, F. et al. Increased availability and open probability of single L-type calcium channels from failing compared with nonfailing human ventricle. Circulation 98, 969-976 (1998).
43. Chen, X. et al. L-type Ca2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ. Res. 91, 517-524 (2002).
44. Mahe, I., Chassany, O., Grenard, A. S., Caulin, C. & Bergmann, J. F. Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction. Am. J. Cardiovasc. Drugs 3, 33-41 (2003).
45. Luo, X. et al. STIM1-dependent store-operated Ca2+ entry is required for pathological cardiac hypertrophy. J. Mol. Cell Cardiol. 52, 136-147 (2012).
46. Parekh, A. B. & Putney, J. W. Jr. Store-operated calcium channels. Physiol. Rev. 85, 757-810 (2005).
47. Vig, M. et al. CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science 312, 1220-1223 (2006).
48. Prakriya, M. et al. Orai1 is an essential pore subunit of the CRAC channel. Nature 443, 230-233 (2006).
49. Liou, J. et al. STIM is a Ca2+ sensor essential for Ca2+-store-depletion- triggered Ca2+ influx. Curr. Biol. 15, 1235-1241 (2005).
50. Roos, J. et al. STIM1, an essential and conserved component of store-operated Ca2+ channel function. J. Cell Biol. 169, 435-445 (2005).
51. Zhang, S. L. et al. Genome-wide RNAi screen of Ca2+ influx identifies genes that regulate Ca2+ release-activated Ca2+ channel activity. Proc. Natl Acad. Sci. USA 103, 9357-9362 (2006).
52. Stathopulos, P. B., Zheng, L., Li, G. Y., Plevin, M. J. & Ikura, M. Structural and mechanistic insights into STIM1-mediated initiation of store-operated calcium entry. Cell 135, 110-122 (2008).
53. Luik, R. M., Wu, M. M., Buchanan, J. & Lewis, R. S. The elementary unit of store-operated Ca2+ entry: local activation of CRAC channels by STIM1 at ER-plasma membrane junctions. J. Cell Biol. 174, 815-825 (2006).
54. Stathopulos, P. B., Li, G. Y., Plevin, M. J., Ames, J. B. & Ikura, M. Stored Ca2+ depletion-induced oligomerization of stromal interaction molecule 1 (STIM1) via the EF-SAM region: an initiation mechanism for capacitive Ca2+ entry. J. Biol. Chem. 281, 35855-35862 (2006).
55. Wu, M. M., Buchanan, J., Luik, R. M. & Lewis, R. S. Ca2+ store depletion causes STIM1 to accumulate in ER regions closely associated with the plasma membrane. J. Cell Biol. 174, 803-813 (2006).
56. Park, C. Y. et al. STIM1 clusters and activates CRAC channels via direct binding of a cytosolic domain to Orai1. Cell 136, 876-890 (2009).
57. Gwack, Y. et al. A genome-wide drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 441, 646-650 (2006).
58. Aubart, F. C. et al. RNA interference targeting STIM1 suppresses vascular smooth muscle cell proliferation and neointima formation in the rat. Mol. Ther. 17, 455-462 (2009).
59. Kurebayashi, N. & Ogawa, Y. Depletion of Ca2+ in the sarcoplasmic reticulum stimulates Ca2+ entry into mouse skeletal muscle fibres. J. Physiol. 533, 185-199 (2001).
60. Pan, Z. et al. Dysfunction of store-operated calcium channel in muscle cells lacking mg29. Nat. Cell Biol. 4, 379-383 (2002).
61. Launikonis, B. S., Barnes, M. & Stephenson, D. G. Identification of the coupling between skeletal muscle store-operated Ca2+ entry and the inositol trisphosphate receptor. Proc. Natl Acad. Sci. USA 100, 2941-2944 (2003).
62. Gibson, A., McFadzean, I., Wallace, P. & Wayman, C. P. Capacitative Ca2+ entry and the regulation of smooth muscle tone. Trends Pharmacol. Sci. 19, 266-269 (1998).
63. Leung, F. P., Yung, L. M., Yao, X., Laher, I. & Huang, Y. Store-operated calcium entry in vascular smooth muscle. Br. J. Pharmacol. 153, 846-857 (2008).
64. Zanou, N. et al. Role of TRPC1 channel in skeletal muscle function. Am. J. Physiol. Cell Physiol. 298, C149-C162 (2010).
65. Ohba, T. et al. Essential role of STIM1 in the development of cardiomyocyte hypertrophy. Biochem. Biophys. Res. Commun. 389, 172-176 (2009).
66. Mulieri, L. A., Hasenfuss, G., Leavitt, B., Allen, P. D. & Alpert, N. R. Altered myocardial force-frequency relation in human heart failure. Circulation 85, 1743-1750 (1992).
67. Pieske, B. et al. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation 92, 1169-1178 (1995).
68. Mercadier, J. J. et al. Altered sarcoplasmic reticulum Ca2+-ATPase gene expression in the human ventricle during end-stage heart failure. J. Clin. Invest. 85, 305-309 (1990).
69. Morgan, J. P. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N. Engl. J. Med. 325, 625-632 (1991).
70. Lindner, M., Erdmann, E. & Beuckelmann, D. J. Calcium content of the sarcoplasmic reticulum in isolated ventricular myocytes from patients with terminal heart failure. J. Mol. Cell Cardiol. 30, 743-749 (1998).
71. Campbell, A. M., Kessler, P. D. & Fambrough, D. M. The alternative carboxyl termini of avian cardiac and brain sarcoplasmic reticulum/endoplasmic reticulum Ca2+-ATPases are on opposite sides of the membrane. J. Biol. Chem. 267, 9321-9325 (1992).
72. Verboomen, H., Wuytack, F., Van den Bosch, L., Mertens, L. & Casteels, R. The functional importance of the extreme C-terminal tail in the gene 2 organellar Ca2+-transport ATPase (SERCA2a/b). Biochem. J. 303, 979-984 (1994).
73. Verboomen, H., Wuytack, F., De Smedt, H., Himpens, B. & Casteels, R. Functional difference between SERCA2a and SERCA2b Ca2+ pumps and their modulation by phospholamban. Biochem. J. 286, 591-595 (1992).
74. Gélébart, P., Martin, V., Enouf, J. & Papp, B. Identification of a new SERCA2 splice variant regulated during monocytic differentiation. Biochem. Biophys. Res. Commun. 303, 676-684 (2003).
75. Dally, S. et al. Ca2+-ATPases in non-failing and failing heart: evidence for a novel cardiac sarco/endoplasmic reticulum Ca2+-ATPase 2 isoform (SERCA2c). Biochem. J. 395, 249-258 (2006).
76. Arai, M., Matsui, H. & Periasamy, M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ. Res. 74, 555-564 (1994).
77. Feldman, A. M., Weinberg, E. O., Ray, P. E. & Lorell, B. H. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ. Res. 73, 184-192 (1993).
78. Kiss, E., Ball, N. A., Kranias, E. G. & Walsh, R. A. Differential changes in cardiac phospholamban and sarcoplasmic reticular Ca2+-ATPase protein levels. Effects on Ca2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. Circ. Res. 77, 759-764 (1995).
79. Zarain-Herzberg, A., Rupp, H., Elimban, V. & Dhalla, N. S. Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir. FASEB J. 10, 1303-1309 (1996).
80. Zarain-Herzberg, A., Afzal, N., Elimban, V. & Dhalla, N. S. Decreased expression of cardiac sarcoplasmic reticulum Ca2+-pump ATPase in congestive heart failure due to myocardial infarction. Mol. Cell Biochem. 163-164, 285-290 (1996).
81. Guo, X., Chapman, D. & Dhalla, N. S. Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan. Mol. Cell Biochem. 254, 163-172 (2003).
82. Arai, M., Alpert, N. R., MacLennan, D. H., Barton, P. & Periasamy, M. Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ. Res. 72, 463-469 (1993).
83. Hasenfuss, G. et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium. Circ. Res. 75, 434-442 (1994).
84. Koss, K. L. & Kranias, E. G. Phospholamban: a prominent regulator of myocardial contractility. Circ. Res. 79, 1059-1063 (1996).
85. Brittsan, A. G. & Kranias, E. G. Phospholamban and cardiac contractile function. J. Mol. Cell Cardiol. 32, 2131-2139 (2000).
86. Movsesian, M. A., Karimi, M., Green, K. & Jones, L. R. Ca2+-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation 90, 653-657 (1994).
87. Schwinger, R. H. et al. Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92, 3220-3228 (1995).
88. Linck, B. et al. Messenger RNA expression and immunological quantification of phospholamban and SR-Ca2+-ATPase in failing and nonfailing human hearts. Cardiovasc. Res. 31, 625-632 (1996).
89. Flesch, M. et al. Sarcoplasmic reticulum Ca2+ ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J. Mol. Med. (Berl.) 74, 321-332 (1996).
90. Meyer, M. et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92, 778-784 (1995).
91. Kranias, E. G. & Hajjar, R. J. Modulation of cardiac contractility by the phopholamban/SERCA2a regulatome. Circ. Res. 110, 1646-1660 (2012).
92. Sande, J. B. et al. Reduced level of serine 16 phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc. Res. 53, 382-391 (2002).
93. Netticadan, T., Temsah, R. M., Kawabata, K. & Dhalla, N. S. Sarcoplasmic reticulum Ca2+/Calmodulin-dependent protein kinase is altered in heart failure. Circ. Res. 86, 596-605 (2000).
94. Mishra, S., Sabbah, H. N., Jain, J. C. & Gupta, R. C. Reduced Ca2+-calmodulin-dependent protein kinase activity and expression in LV myocardium of dogs with heart failure. Am. J. Physiol. Heart Circ. Physiol. 284, H876-H883 (2003).
95. Huang, B., Wang, S., Qin, D., Boutjdir, M. & El-Sherif, N. Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of β-adrenergic pathway, Gi protein, phosphodiesterase, and phosphatases. Circ. Res. 85, 848-855 (1999).
96. Schwinger, R. H. et al. Reduced Ca2+-sensitivity of SERCA2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J. Mol. Cell Cardiol. 31, 479-491 (1999).
97. Nicolaou, P., Hajjar, R. J. & Kranias, E. G. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J. Mol. Cell Cardiol. 47, 365-371 (2009).
98. Yamada, M. et al. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J. 20, 1197-1199 (2006).
99. Medeiros, A. et al. Mutations in the human phospholamban gene in patients with heart failure. Am. Heart J. 162, 1088.e1-1095.e1 (2011).
100. Schmitt, J. P. et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299, 1410-1413 (2003).
101. Haghighi, K. et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl Acad. Sci. USA 103, 1388-1393 (2006).
102. Haghighi, K. et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111, 869-876 (2003).
103. Bers, D. M. & Weber, C. R. Na/Ca exchange function in intact ventricular myocytes. Ann. N. Y. Acad. Sci. 976, 500-512 (2002).
104. Studer, R. et al. Gene expression of the cardiac Na+-Ca2+ exchanger in end-stage human heart failure. Circ. Res. 75, 443-453 (1994).
105. Hasenfuss, G. et al. Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 99, 641-648 (1999).
106. Schwinger, R. H. et al. Reduced sodium pump α1, α3, and β1-isoform protein levels and Na+, K+-ATPase activity but unchanged Na+-Ca2+ exchanger protein levels in human heart failure. Circulation 99, 2105-2112 (1999).
107. Piper, C. et al. Is myocardial Na+/Ca2+ exchanger transcription a marker for different stages of myocardial dysfunction? Quantitative polymerase chain reaction of the messenger RNA in endomyocardial biopsies of patients with heart failure. J. Am. Coll. Cardiol. 36, 233-241 (2000).
108. Flesch, M. et al. Evidence for functional relevance of an enhanced expression of the Na+-Ca2+ exchanger in failing human myocardium. Circulation 94, 992-1002 (1996).
109. Reinecke, H., Studer, R., Vetter, R., Holtz, I. & Drexler, H. Cardiac Na+/Ca2+ exchange activity in patients with end-stage heart failure. Cardiovasc. Res. 31, 48-54 (1996).
110. Piacentino, V. 3rd et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ. Res. 92, 651-658 (2003).
111. Weber, C. R., Piacentino, V. 3rd, Houser, S. R. & Bers, D. M. Dynamic regulation of sodium/calcium exchange function in human heart failure. Circulation 108, 2224-2229 (2003).
112. Bers, D. M., Eisner, D. A. & Valdivia, H. H. Sarcoplasmic reticulum Ca2+ and heart failure: roles of diastolic leak and Ca2+ transport. Circ. Res. 93, 487-490 (2003).
113. Györke, S., Stevens, S. C. & Terentyev, D. Cardiac calsequestrin: quest inside the SR. J. Physiol. 587 (Pt 13), 3091-3094 (2009).
114. Györke, S. & Terentyev, D. Modulation of ryanodine receptor by luminal calcium and accessory proteins in health and cardiac disease. Cardiovasc. Res. 77, 245-255 (2008).
115. Knollmann, B. C. New roles of calsequestrin and triadin in cardiac muscle. J. Physiol. 587, 3081-3087 (2009).
116. Kontula, K. et al. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights. Cardiovasc. Res. 67, 379-387 (2005).
117. Postma, A. V. et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ. Res. 91, e21-e26 (2002).
118. Lahat, H. et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am. J. Hum. Genet. 69, 1378-1384 (2001).
119. Song, L. et al. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J. Clin. Invest. 117, 1814-1823 (2007).
120. Kiarash, A. et al. Defective glycosylation of calsequestrin in heart failure. Cardiovasc. Res. 63, 264-272 (2004).
121. Houle, T. D., Ram, M. L., McMurray, W. J. & Cala, S. E. Different endoplasmic reticulum trafficking and processing pathways for calsequestrin (CSQ) and epitope-tagged CSQ. Exp. Cell Res. 312, 4150-4161 (2006).
122. McFarland, T. P., Milstein, M. L. & Cala, S. E. Rough endoplasmic reticulum to junctional sarcoplasmic reticulum trafficking of calsequestrin in adult cardiomyocytes. J. Mol. Cell Cardiol. 49, 556-564 (2010).
123. Zhang, L., Kelley, J., Schmeisser, G., Kobayashi, Y. M. & Jones, L. R. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. J. Biol. Chem. 272, 23389-23397 (1997).
124. Gergs, U. et al. On the role of junctin in cardiac Ca2+ handling, contractility, and heart failure. Am. J. Physiol. Heart Circ. Physiol. 293, H728-H734 (2007).
125. Terentyev, D. et al. Triadin overexpression stimulates excitation-contraction coupling and increases predisposition to cellular arrhythmia in cardiac myocytes. Circ. Res. 96, 651-658 (2005).
126. Engelhardt, S. et al. Early impairment of calcium handling and altered expression of junctin in hearts of mice overexpressing the β1-adrenergic receptor. FASEB J. 15, 2718-2720 (2001).
127. Pritchard, T. J. & Kranias, E. G. Junctin and the histidine-rich Ca2+ binding protein: potential roles in heart failure and arrhythmogenesis. J. Physiol. 587, 3125-3133 (2009).
128. Fan, G. C., Gregory, K. N., Zhao, W., Park, W. J. & Kranias, E. G. Regulation of myocardial function by histidine-rich, calcium-binding protein. Am. J. Physiol. Heart Circ. Physiol. 287, H1705-H1711 (2004).
129. Arvanitis, D. A. et al. The Ser96Ala variant in histidine-rich calcium-binding protein is associated with life-threatening ventricular arrhythmias in idiopathic dilated cardiomyopathy. Eur. Heart J. 29, 2514-2525 (2008).
130. Kiewitz, R., Lyons, G. E., Schafer, B. W. & Heizmann, C. W. Transcriptional regulation of S100A1 and expression during mouse heart development. Biochim. Biophys. Acta 1498, 207-219 (2000).
131. Volkers, M. et al. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 41, 135-143 (2007).
132. Remppis, A. et al. Altered expression of the Ca2+-binding protein S100A1 in human cardiomyopathy. Biochim. Biophys. Acta 1313, 253-257 (1996).
133. Most, P. et al. Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J. Biol. Chem. 278, 33809-33817 (2003).
134. Kettlewell, S., Most, P., Currie, S., Koch, W. J. & Smith, G. L. S100A1 increases the gain of excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes. J. Mol. Cell Cardiol. 39, 900-910 (2005).
135. Du, X. J. et al. Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol. Cell. Biol. 22, 2821-2829 (2002).
136. Boerries, M. et al. Ca2+-dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol. Cell Biol. 27, 4365-4373 (2007).
137. Wehrens, X. H. & Marks, A. R. Altered function and regulation of cardiac ryanodine receptors in cardiac disease. Trends Biochem. Sci. 28, 671-678 (2003).
138. Kushnir, A. & Marks, A. R. The ryanodine receptor in cardiac physiology and disease. Adv. Pharmacol. 59, 1-30 (2010).
139. Avila, G., O'Connell, K. M., Groom, L. A. & Dirksen, R. T. Ca2+ release through ryanodine receptors regulates skeletal muscle L-type Ca2+ channel expression. J. Biol. Chem. 276, 17732-17738 (2001).
140. Lanner, J. T., Georgiou, D. K., Joshi, A. D. & Hamilton, S. L. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb. Perspect. Biol. 2, a003996 (2010).
141. Song, D. W., Lee, J. G., Youn, H. S., Eom, S. H. & Kim do, H. Ryanodine receptor assembly: a novel systems biology approach to 3D mapping. Prog. Biophys. Mol. Biol. 105, 145-161 (2011).
142. Balshaw, D. M., Xu, L., Yamaguchi, N., Pasek, D. A. & Meissner, G. Calmodulin binding and inhibition of cardiac muscle calcium release channel (ryanodine receptor). J. Biol. Chem. 276, 20144-20153 (2001).
143. Zhang, T. et al. The δC isoform of CAMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ. Res. 92, 912-919 (2003).
144. Sharma, M. R., Jeyakumar, L. H., Fleischer, S. & Wagenknecht, T. Three-dimensional visualization of FKBP12.6 binding to an open conformation of cardiac ryanodine receptor. Biophys. J. 90, 164-172 (2006).
145. Xiao, B. et al. Ser-2030, but not Ser-2808, is the major phosphorylation site in cardiac ryanodine receptors responding to protein kinase A activation upon β-adrenergic stimulation in normal and failing hearts. Biochem. J. 396, 7-16 (2006).
146. Marx, S. O. et al. Phosphorylation-dependent regulation of ryanodine receptors: a novel role for leucine/isoleucine zippers. J. Cell Biol. 153, 699-708 (2001).
147. Lee, E. H. et al. N-terminal region of FKBP12 is essential for binding to the skeletal ryanodine receptor. J. Biol. Chem. 279, 26481-26488 (2004).
148. Shan, J. et al. Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice. J. Clin. Invest. 120, 4375-4387 (2010).
149. Shannon, T. R. & Lew, W. Y. Diastolic release of calcium from the sarcoplasmic reticulum: a potential target for treating triggered arrhythmias and heart failure. J. Am. Coll. Cardiol. 53, 2006-2008 (2009).
150. Go, L. O. et al. Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. J. Clin. Invest. 95, 888-894 (1995).
151. Sainte Beuve, C. et al. Cardiac calcium release channel (ryanodine receptor) in control and cardiomyopathic human hearts: mRNA and protein contents are differentially regulated. J. Mol. Cell Cardiol. 29, 1237-1246 (1997).
152. Hain, J., Onoue, H., Mayrleitner, M., Fleischer, S. & Schindler, H. Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle. J. Biol. Chem. 270, 2074-2081 (1995).
153. Marx, S. O. et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365-376 (2000).
154. Valdivia, H. H., Kaplan, J. H., Ellis-Davies, G. C. & Lederer, W. J. Rapid adaptation of cardiac ryanodine receptors: modulation by Mg2+ and phosphorylation. Science 267, 1997-2000 (1995).
155. Xiao, B. et al. Characterization of a novel PKA phosphorylation site, serine-2030, reveals no PKA hyperphosphorylation of the cardiac ryanodine receptor in canine heart failure. Circ. Res. 96, 847-855 (2005).
156. Reiken, S. et al. PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure. J. Cell Biol. 160, 919-928 (2003).
157. Yano, M. et al. Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca2+ leak through ryanodine receptor in heart failure. Circulation 102, 2131-2136 (2000).
158. Ono, K. et al. Altered interaction of FKBP12.6 with ryanodine receptor as a cause of abnormal Ca2+ release in heart failure. Cardiovasc. Res. 48, 323-331 (2000).
159. Priori, S. G. et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103, 196-200 (2001).
160. Cerrone, M. et al. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ. Res. 96, e77-e82 (2005).
161. Nicol, R. L., Frey, N. & Olson, E. N. From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease. Annu. Rev. Genomics Hum. Genet. 1, 179-223 (2000).
162. Li, H., Rao, A. & Hogan, P. G. Interaction of calcineurin with substrates and targeting proteins. Trends Cell Biol. 21, 91-103 (2010).
163. Molkentin, J. D. Calcineurin and beyond: cardiac hypertrophic signaling. Circ. Res. 87, 731-738 (2000).
164. Molkentin, J. D. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc. Res. 63, 467-475 (2004).
165. Molkentin, J. D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215-228 (1998).
166. Molkentin, J. D. & Olson, E. N. GATA4: a novel transcriptional regulator of cardiac hypertrophy? Circulation 96, 3833-3835 (1997).
167. Lim, H. W. et al. Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. J. Mol. Cell Cardiol. 32, 697-709 (2000).
168. Frey, N. & Olson, E. N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65, 45-79 (2003).
169. Meguro, T. et al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ. Res. 84, 735-740 (1999).
170. Sussman, M. A. et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281, 1690-1693 (1998).
171. Ding, B. et al. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ. Res. 84, 729-734 (1999).
172. Luo, Z., Shyu, K. G., Gualberto, A. & Walsh, K. Calcineurin inhibitors and cardiac hypertrophy. Nat. Med. 4, 1092-1093 (1998).
173. Anderson, M. E., Brown, J. H. & Bers, D. M. CaMKII in myocardial hypertrophy and heart failure. J. Mol. Cell Cardiol. 51, 468-473 (2011).
174. Hoch, B., Meyer, R., Hetzer, R., Krause, E. G. & Karczewski, P. Identification and expression of δ-isoforms of the multifunctional Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human myocardium. Circ. Res. 84, 713-721 (1999).
175. Kirchhefer, U., Schmitz, W., Scholz, H. & Neumann, J. Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. Cardiovasc. Res. 42, 254-261 (1999).
176. Maier, L. S. et al. Transgenic CaMKIIδC overexpression uniquely alters cardiac myocyte Ca2+ handling: reduced SR Ca2+ load and activated SR Ca2+ release. Circ. Res. 92, 904-911 (2003).
177. Zhang, R. et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat. Med. 11, 409-417 (2005).
178. Wu, Y. et al. Suppression of dynamic Ca2+ transient responses to pacing in ventricular myocytes from mice with genetic calmodulin kinase II inhibition. J. Mol. Cell Cardiol. 40, 213-223 (2006).
179. Li, J. et al. Calmodulin kinase II inhibition shortens action potential duration by upregulation of K+ currents. Circ. Res. 99, 1092-1099 (2006).
180. Grueter, C. E., Colbran, R. J. & Anderson, M. E. CaMKII, an emerging molecular driver for calcium homeostasis, arrhythmias, and cardiac dysfunction. J. Mol. Med. (Berl.) 85, 5-14 (2007).
181. Bartel, S. et al. Phosphorylation of phospholamban at threonine-17 in the absence and presence of β-adrenergic stimulation in neonatal rat cardiomyocytes. J. Mol. Cell Cardiol. 32, 2173-2185 (2000).
182. Hagemann, D. & Xiao, R. P. Dual site phospholamban phosphorylation
183. Mattiazzi, A., Mundiña-Weilenmann, C., Guoxiang, C., Vittone, L. & Kranias, E. Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions. Cardiovasc. Res. 68, 366-375 (2005).
184. Brixius, K., Wollmer, A., Bölck, B., Mehlhorn, U. & Schwinger, R. H. Ser16- but not Thr17-phosphorylation of phospholamban influences frequency-dependent force generation in human myocardium. Pflugers Arch. 447, 150-157 (2003).
185. Hagemann, D. et al. Frequency-encoding Thr17 phospholamban phosphorylation is independent of Ser16 phosphorylation in cardiac myocytes. J. Biol. Chem. 275, 22532-22536 (2000).
186. Ji, Y. et al. Targeted inhibition of Ca2+/calmodulin-dependent protein kinase II in cardiac longitudinal sarcoplasmic reticulum results in decreased phospholamban phosphorylation at threonine 17. J. Biol. Chem. 278, 25063-25071 (2003).
187. Wehrens, X. H. et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304, 292-296 (2004).
188. Li, L., Satoh, H., Ginsburg, K. S. & Bers, D. M. The effect of Ca2+-calmodulin-dependent protein kinase II on cardiac excitation-contraction coupling in ferret ventricular myocytes. J. Physiol. 501, 17-31 (1997).
189. Maier, L. S. et al. Transgenic CaMKIIdeltaC overexpression uniquely alters cardiac myocyte Ca2+ handling: reduced SR Ca2+ load and activated SR Ca2+ release. Circ. Res. 92, 904-911 (2003).
190. Dzhura, I., Wu, Y., Colbran, R. J., Balser, J. R. & Anderson, M. E. Calmodulin kinase determines calcium-dependent facilitation of L-type calcium channels. Nat. Cell Biol. 2, 173-177 (2000).
191. Grueter, C. E. et al. L-type Ca2+ channel facilitation mediated by phosphorylation of the β subunit by CaMKII. Mol. Cell 23, 641-650 (2006).
192. Wu, Y. et al. Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation 106, 1288-1293 (2002).
193. Muller, O. J. et al. Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload. Cardiovasc. Res. 59, 380-389 (2003).
194. del Monte, F. et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100, 2308-2311 (1999).
195. Prunier, F. et al. Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation 118, 614-624 (2008).
196. Kawase, Y. et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J. Am. Coll. Cardiol. 51, 1112-1119 (2008).
197. del Monte, F. et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+-ATPase in a rat model of heart failure. Circulation 104, 1424-1429 (2001).
198. Sakata, S. et al. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J. Mol. Cell Cardiol. 42, 852-861 (2007).
199. Miyamoto, M. I. et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc. Natl. Acad. Sci. USA 97, 793-798 (2000).
200. del Monte, F. et al. Transcriptional changes following restoration of SERCA2a levels in failing rat hearts. FASEB J. 18, 1474-1476 (2004).
201. Nayak, S. & Herzog, R. W. Progress and prospects: immune responses to viral vectors. Gene Ther. 17, 295-304 (2010).
202. Asokan, A., Schaffer, D. V. & Samulski, R. J. The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699-708 (2012).
203. Mariani, J. A. et al. Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur. J. Heart Fail. 13, 247-253 (2011).
204. del Monte, F. et al. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc. Natl Acad. Sci. USA 101, 5622-5627 (2004).
205. Cutler, M. J., Wan, X., Laurita, K. R., Hajjar, R. J. & Rosenbaum, D. S. Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. Circ. Arrhythm. Electrophysiol. 2, 686-694 (2009).
206. Lyon, A. R. et al. SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ. Arrhythm. Electrophysiol. 4, 362-372 (2011).
207. Chen, Y. et al. Constitutive cardiac overexpression of sarcoplasmic/endoplasmic reticulum Ca2+-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation 109, 1898-1903 (2004).
208. Davia, K. et al. SERCA2a overexpression decreases the incidence of aftercontractions in adult rabbit ventricular myocytes. J. Mol. Cell. Cardiol. 33, 1005-1015 (2001).
209. Jaski, B. E. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. J. Card. Fail. 15, 171-181 (2009).
210. Jessup, M. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124, 304-313 (2011).
211. Eizema, K. et al. Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter. Circulation 101, 2193-2199 (2000).
212. Hoshijima, M. et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8, 864-871 (2002).
213. Dieterle, T. et al. Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. Cardiovasc. Res. 67, 678-688 (2005).
214. Watanabe, A. et al. Phospholamban ablation by RNA interference increases Ca2+ uptake into rat cardiac myocyte sarcoplasmic reticulum. J. Mol. Cell Cardiol. 37, 691-698 (2004).
215. Suckau, L. et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119, 1241-1252 (2009).
216. Neumann, J. et al. Evidence for physiological functions of protein phosphatases in the heart: evaluation with okadaic acid. Am. J. Physiol. 265, H257-H266 (1993).
217. Hubbard, M. J. & Cohen, P. On target with a new mechanism for the regulation of protein phosphorylation. Trends Biochem. Sci. 18, 172-177 (1993).
218. Steenaart, N. A., Ganim, J. R., Di Salvo, J. & Kranias, E. G. The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme. Arch. Biochem. Biophys. 293, 17-24 (1992).
219. Neumann, J. et al. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J. Mol. Cell Cardiol. 29, 265-272 (1997).
220. Gupta, R. C. et al. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am. J. Physiol. Heart Circ. Physiol. 285, H2373-H2381 (2003).
221. Nicolaou, P., Hajjar, R. J. & Kranias, E. G. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J. Mol. Cell Cardiol. 47, 365-371 (2009).
222. Carr, A. N. et al. Type 1 phosphatase, a negative regulator of cardiac function. Mol. Cell Biol. 22, 4124-4135 (2002).
223. El-Armouche, A. et al. Evidence for protein phosphatase inhibitor-1 playing an amplifier role in β-adrenergic signaling. FASEB J. 17, 437-439 (2003).
224. El-Armouche, A., Pamminger, T., Ditz, D., Zolk, O. & Eschenhagen, T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc. Res. 61, 87-93 (2004).
225. Pathak, A. et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ. Res. 96, 756-766 (2005).
226. Nicolaou, P. et al. Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ. Res. 104, 1012-1020 (2009).
227. Wittköpper, K. et al. Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J. Clin. Invest. 120, 617-626 (2010).
228. Kawashima, H. et al. Protein phosphatase inhibitor-1 augments a protein kinase A-dependent increase in the Ca2+ loading of the sarcoplasmic reticulum without changing its Ca2+ release. Circ. J. 73, 1133-1140 (2009).
229. Geiss-Friedlander, R. & Melchior, F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 8, 947-956 (2007).
230. Woo, C. H. & Abe, J. SUMO - a post-translational modification with therapeutic potential? Curr. Opin. Pharmacol. 10, 146-155 (2010).
231. Jakobs, P. M. et al. Novel lamin A/C mutations in two families with dilated cardiomyopathy and conduction system disease. J. Card. Fail. 7, 249-256 (2001).
232. Zhang, Y. Q. & Sarge, K. D. Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies. J. Cell Biol. 182, 35-39 (2008).
233. Kho, C. et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature 477, 601-605 (2011).
234. Wehrens, X. H. et al. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc. Natl Acad. Sci. USA 103, 511-518 (2006).
235. Belevych, A. E. et al. The relationship between arrhythmogenesis and impaired contractility in heart failure: role of altered ryanodine receptor function. Cardiovasc. Res. 90, 493-502 (2011).
236. Loughrey, C. M. et al. Over-expression of FK506-binding protein FKBP12.6 alters excitation-contraction coupling in adult rabbit cardiomyocytes. J. Physiol. 556, 919-934 (2004).
237. Huang, F., Shan, J., Reiken, S., Wehrens, X. H. & Marks, A. R. Analysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: rescue of heart failure by calstabin2 in mice. Proc. Natl Acad. Sci. USA 103, 3456-3461 (2006).
238. Xu, L., Tripathy, A., Pasek, D. A. & Meissner, G. Potential for pharmacology of ryanodine receptor/calcium release channels. Ann. N. Y. Acad. Sci. 853, 130-148 (1998).
239. McCauley, M. D. & Wehrens, X. H. Targeting ryanodine receptors for anti-arrhythmic therapy. Acta Pharmacol. Sin. 32, 749-757 (2011).
240. Kaneko, N. New 1,4-benzothiazepine derivative, K201, demonstrates cardioprotective effects against sudden cardiac cell death and intracellular calcium blocking action. Drug Dev. Res. 33, 429-438 (1994).
241. Hunt, D. J. et al. K201 (JTV519) suppresses spontaneous Ca2+ release and 3H ryanodine binding to RyR2 irrespective of FKBP12.6 association. Biochem. J. 404, 431-438 (2007).
242. Inagaki, K., Kihara, Y., Izumi, T. & Sasayama, S. The cardioprotective effects of a new 1,4-benzothiazepine derivative, JTV519, on ischemia/reperfusion-induced Ca2+ overload in isolated rat hearts. Cardiovasc. Drugs Ther. 14, 489-495 (2000).
243. Kumagai, K., Nakashima, H., Gondo, N. & Saku, K. Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J. Cardiovasc. Electrophysiol. 14, 880-884 (2003).
244. Kohno, M. et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am. J. Physiol. Heart Circ. Physiol. 284, H1035-H1042 (2003).
245. Ito, K. et al. JTV-519, a novel cardioprotective agent, improves the contractile recovery after ischaemia-reperfusion in coronary perfused guinea-pig ventricular muscles. Br. J. Pharmacol. 130, 767-776 (2000).
246. Inagaki, K. et al. Anti-ischemic effect of a novel cardioprotective agent, JTV519, is mediated through specific activation of δ-isoform of protein kinase C in rat ventricular myocardium. Circulation 101, 797-804 (2000).
247. Toischer, K. et al. K201 improves aspects of the contractile performance of human failing myocardium via reduction in Ca2+ leak from the sarcoplasmic reticulum. Basic Res. Cardiol. 105, 279-287 (2010).
248. Liu, N. et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ. Res. 99, 292-298 (2006).
249. Bellinger, A. M. et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat. Med. 15, 325-330 (2009).
250. Fauconnier, J. et al. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc. Natl Acad. Sci. USA 107, 1559-1564 (2010).
251. International Standard Randomised Controlled Trial Number Register. Controlled-trials.com [online] http://www.controlled-trials.com/ISRCTN14227980 (2012).
252. Currie, S., Elliott, E. B., Smith, G. L. & Loughrey, C. M. Two candidates at the heart of dysfunction: the ryanodine receptor and calcium/calmodulin protein kinase II as potential targets for therapeutic intervention - an in vivo perspective. Pharmacol. Ther. 131, 204-220 (2011).
253. Sossalla, S. et al. Inhibition of elevated Ca2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ. Res. 107, 1150-1161 (2010).
254. Li, G., Hidaka, H. & Wollheim, C. B. Inhibition of voltage-gated Ca2+ channels and insulin secretion in HIT cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-62: comparison with antagonists of calmodulin and L-type Ca2+ channels. Mol. Pharmacol. 42, 489-488 (1992).
255. Hvalby, O. et al. Specificity of protein kinase inhibitor peptides and induction of long-term potentiation. Proc. Natl Acad. Sci. USA 91, 4761-4765 (1994).
256. Remppis, A. et al. Altered expression of the Ca2+-binding protein S100A1 in human cardiomyopathy. Biochim. Biophys. Acta 1313, 253-257 (1996).
257. Most, P. et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J. Clin. Invest. 114, 1550-1563 (2004).
258. Most, P. et al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 114, 1258-1268 (2006).
259. Pleger, S. T. et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 115, 2506-2515 (2007).
260. Brinks, H. et al. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J. Am. Coll. Cardiol. 58, 966-973 (2011).
261. Pleger, S. T. et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci. Transl. Med. 3, 92ra64 (2011).
262. Yano, M. et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107, 477-484 (2003).
263. Wehrens, X. H. et al. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function. Proc. Natl Acad. Sci. USA 102, 9607-9612 (2005).